Braak stage 1, 100% of pigmented neurons left
parkinsonconnecting

Gene record

FDFT1

farnesyl-diphosphate farnesyltransferase 1

translation score 0.53, read 2026-10-26; 2 sealed predictions, 0 held; 3 receipts.

Six readers

readerfoundscore
genetics
Open Targets		no genetic evidence; overall 0.01 from other evidence0.00
cell type
Human Protein Atlas		cell type enhanced, including oligodendrocytes; strongest in late primary spermatocytes0.75
chemistry
Open Targets		compounds already reach it: lapaquistat acetate0.90
trials
ClinicalTrials.gov		no Parkinson's trials on record: an open field1.00
literature
PubMed		2 Parkinson's papers of 2760.85
pathways
Reactome		3 pathways; mostly other0.30

No case: the score is under the bar. Receipt 11054

Sealed predictions

  1. FDFT1 in dopamine neurons, braak+0.12 (p 0.749) → +0.28 (p 0.470)receipt 11062
  2. FDFT1 in oligodendrocytes, braak+0.43 (p 0.243) → -0.43 (p 0.249)receipt 11061

Swarm cases

receipt 11062: FDFT1 in dopamine neurons, braak

power
full sample +0.22 (p 0.389, n 18), 95% CI -0.28 to +0.62. the interval is wide: not enough donors to tell.
confounder
adjusted for sex: +0.24 (p 0.337, n 18). does not hold up.
composition
dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.24 (p 0.328, n 18). could be the mix.
skeptic
leave-one-out range +0.11 to +0.35, sign flips 0; without severely affected donors +0.22 (p 0.389, n 18). fragile.
cell type
no other cell group does better.
axis
no measure beats "tracks Braak Lewy-body stage" for FDFT1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 11061: FDFT1 in oligodendrocytes, braak

power
full sample +0.07 (p 0.787, n 18), 95% CI -0.41 to +0.52. the interval is wide: not enough donors to tell.
confounder
adjusted for sex: +0.17 (p 0.498, n 18). does not hold up.
composition
oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.22 (p 0.389, n 18). could be the mix.
skeptic
leave-one-out range -0.07 to +0.16, sign flips 2; without severely affected donors +0.07 (p 0.787, n 18). fragile.
cell type
no other cell group does better.
axis
no measure beats "tracks Braak Lewy-body stage" for FDFT1 in oligodendrocytes.

case closed: nothing better to follow up.

Receipts

loading the receipts